Optimizing Alpha & Beta Isotope Supply & Manufacturing to Increase Capacity from Preclinical Studies to Clinical Trials & Prepare for Phase 3 to Commercialization & Scale Radioisotope Therapies to Reality
With billion dollar acquisitions from BMS, Eli Lilly, Sanofi and AstraZeneca validating the commercial opportunity of radiopharmaceutical therapies, clinical programs are accelerating into Phase II/III at unprecedented speed. Yet the infrastructure required to sustain this growth is under immense strain. Isotope demand is outpacing global production; half lives leave no margin for error, and the gap between scientific ambition and operational capability is widening across the industry.
The question isn’t whether the science works. It’s whether you can deliver it.
The 4th TRP Supply Chain & Manufacturing Summit is the only industry meeting dedicated entirely to solving these challenges, bringing together the senior leaders responsible for turning pipelines into real, deliverable therapies.
In 2026, the stakes are higher than ever. As infrastructure struggles to keep pace and competition intensifies, the companies that solve supply, scale, and distribution first will define the future of radiopharmaceutical medicine.
Join the organizations leading the charge or risk being left behind.
Attending Companies Include: